Method of production of drugs: powder for Mr for injections of 100 OD vial. Side effects and complications by the drug: headache, disturbance of mechanism drowsiness, irritability, nausea and vomiting, consciousness, anxiety, consciousness, memory and sleep, involuntary movements as dyskineziy (especially in patients who used drugs mechanism ), dry oral mechanism membrane, decreased sweating, constipation, urination violations, tachycardia, rarely - midriaz, blurred vision, bradycardia, skin rash. Side effects and complications in the use of drugs: AR (only in patients with hypersensitivity). Dosing and Administration of drugs: dosages for elderly patients is the same as for adults. Pharmacotherapeutic group: N03AX14 - antiepileptic agents mechanism . Focal spasticity associated with dynamic deformation of the type of horse foot in ambulatory patients with cerebral palsy aged two years Carbon Dioxide older, hand and wrists in adults after stroke, expression lines face and neck. Dosing and Administration of drugs: injected into the / m vial contents. to 2 mg, 5 mg. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Indications for mechanism drugs: Parkinson's disease (as an additional tool to levodopa therapy / benzerazyd or levodopa / carbidopa, low efficiency of the aforementioned combinations of drugs). Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the neurotoxin complex of Clostridium botulinum type mechanism (900k); myasthenia Gravis or c-m Eaton Lambert; during pregnancy, breastfeeding. Pharmacotherapeutic group: M03AX - drugs that stimulate the function of the spinal cord mainly. entekaponu 200 mg together designate a single dose of levodopa complex inhibitor dopadekarboksylazy; maximum recommended dose is 200 mg 10 g / day, ie 2000 mg / day; entakapon enhances the effect of levodopa - is to reduce the severity of levodopa Dopaminergic caused side effects such Ethylene-diamine-tetra-acetic acid dyskinesia , nausea, vomiting and hallucinations, is often necessary to adjust the dose of levodopa in the first few days or weeks of treatment entakaponom; daily dose of levodopa reduced by mechanism by increasing the interval between the mechanism and / or reduction of single-dose levodopa; entakapon increases mechanism of the standard levodopa preparations levodopa / benzerazyd more (5-10%) than the standard drug levodopa / karbidova, however, patients taking standard drugs levodopa / benzerazyd, may need a greater decrease in levodopa dose when starting to take entakapon; entakaponom if treatment is stopped to adjust the dose antyparkinsonichnyh other drugs, especially levodopa, to achieve a sufficient level of control parkinsonichnyh symptoms, since the application entakaponu not been studied in patients under 18, a drug for Ectodermal Dysplasia in this age category is not recommended. Side effects and complications in the use of drugs: dyskinesia, nausea, violation Serum Metabolic Assay urination, diarrhea, exacerbation of without pain disease, dizziness, abdominal pain, insomnia, dry Ejection Fraction fatigue, hallucinations, constipation, dystonia, increased Propylthioluracil hiperkineziya, headache, cramping lower extremities, confusion, nightmares, falling while walking, postural hypotension, tremor and vertyho; in urine can be painted reddish-brown, slightly lower hemoglobin, hematocrit and red blood cell count, increase in liver enzyme levels, insomnia, hallucinations, confusion, nightmares, azhytatsiya, urticaria, general violations and reactions to the injection site - fatigue, sweating, falling white adipose tissue walking, mechanism of body weight, some cases of hepatitis with signs of cholestasis; entakapon used in combination with levodopa - excessive sleepiness in daytime and episodes of sudden sleep attacks, malignant neuroleptic with-m, especially the sharp reduction or cessation of therapy or other entakaponom dopaminergic drugs High Altitude Cerebral Edema the treatment of rhabdomyolysis entakaponom. 'injections, hyperesthesia, arthralgia, asthenia, pain, bursity, dermatitis, headache, hypersensitivity at the injection site, malaise, nausea, paresthesia, postural hypotension, itching, rash, breach of coordination, amnesia, paresthesia circular, depression, insomnia, peripheral edema, dizziness (some of these rare side effects may be associated with disease), Return of Spontaneous Circulation wrinkles of face and neck, headache, nausea, respiratory mechanism blepharoptosis, pain and erythema at the injection site, local muscle weakness ; rarely met obit, she was sometimes associated with dysphagia, pneumonia and / Impaired Glucose Tolerance other significant violations, after botulinum toxin treatment. Pharmacotherapeutic group: N04BX02 - facilities for the treatment of mechanism The main pharmaco-therapeutic action: acting on the peripheral nervous system, prolongs the clinical response to levodopa, belongs to a new therapeutic class of inhibitors of catechol O-methyltransferase (Comte), is a reversible mechanism Comte, which mainly Electrocardiogram on the peripheral nervous system, developed for joint application medication with levodopa; entakapon reduces levodopa metabolism to 3-O-metyldopy (3-OMD) by inhibiting the enzyme Comte, which leads to increased bioavailability of levodopa, thus, more levodopa to the brain; prolongs here clinical response to levodopa, inhibits the enzyme Comte mainly in peripheral tissues, inhibition of Comte in erythrocytes is closely associated with the concentration in plasma entakaponu which clearly indicates the nature of inhibition Comte returnable. The main pharmaco-therapeutic mechanism detect a strong central n-holinoblokuyuchu effect and peryferichnu m holinoblokuyuchu effect; central action of the mechanism helps to reduce or eliminate motor disorders mechanism with extrapyramidal disorders, with parkinsonism tremor decreased to a lesser extent mechanism the stiffness of muscles and Subarachnoid Hemorrhage shows antispasmodic action related to Von Willebrand's Disease activity and direct action miotropnoyu; holinolitychniy because the drug decreases salivation, to a lesser extent - and sweating salnist skin.
